UPC CFI 552/2025
Jun 18, 2025·EP3854403: USE OF SUBSTITUTED AMINOPROPIONATE COMPOUNDS IN TREATMENT OF SARS-COV-2 INFECTION
- Case details
- StatusInterim PhaseActionRevocationCategoryMain Revocation Action
- Parties
- ClaimantsReps: Christine Kanz (Hoyng Rokh Monegier); Amandine Métier (Hoyng-Rokh-Monegier Paris); Peter van Schijndel (Hoyng-Rokh-Monegier Amsterdam)RespondentsReps: Camille Pecnard (LAVOIX); Pierre-Emanuel Meynard (LAVOIX); Charlotte Cuny (LAVOIX); Béatrice Holz (LAVOIX); Aude Veynante Gardey (LAVOIX); Michael Schlauch (LAVOIX)
- Division
- Milan CD
- Technology
- Pharmaceuticals · Small Molecule · Organic Chemistry
- Language
- English
- First decided
- May 4, 2026
- 2026-05-04RevokedRevocation meritsRevocation Action
The Central Division (Milan seat) revoked European Patent EP 3854403 in its entirety, finding that the patent lacks inventive step. The attack based on insufficient disclosure was dismissed, but all amendment requests (main request and eight auxiliary requests) were also dismissed as none overcame the inventive step objection. The defendant (patent proprietor) bears the legal costs fixed by party agreement at €800,000.
Legal issues:Inventive step (Art. 56 EPC) — whether use of Remdesivir against SARS-CoV-2 was obvious at priority date given prior art on broad-spectrum coronavirus activitySufficiency of disclosure (Art. 83 EPC / Art. 138(1)(b) EPC) — whether undefined stereochemistry at phosphorus in Formula I rendered claims insufficiently disclosedApplication to amend patent (Main Request and Auxiliary Requests 1-8) — admissibility and allowability under Art. 123 and 84 EPCDefinition of person skilled in the art and common general knowledge at priority date (21 January 2020)Reasonable expectation of success vs. mere hope of success in the context of emerging viral diseaseValue of proceedings and recoverable costs under Art. 69 UPCA
| Document title | Date | Public |
|---|---|---|
| action.phaseChange.caseClose | 2026-05-05 | Not public |
| action.issueDecision.decision | 2026-05-04 | Not public |
| Decision | 2026-05-04 | Public |
| action.communication.general | 2026-05-03 | Not public |
| action.communication.general | 2026-04-16 | Not public |
| Other Documents | 2026-04-16 | Not public |
| Receipt | 2026-04-15 | Not public |
| Cover sheet | 2026-04-15 | Not public |
| Document | 2026-04-15 | Not public |
| action.communication.general | 2026-04-14 | Not public |
| action.communication.general | 2026-04-14 | Not public |
| Receipt | 2026-04-13 | Not public |
| Cover sheet | 2026-04-13 | Not public |
| Exhibit Claimant | 2026-04-13 | Not public |
| Exhibit Claimant | 2026-04-13 | Not public |
| Document Claimant | 2026-04-13 | Not public |
| Receipt | 2026-04-13 | Not public |
| Cover sheet | 2026-04-13 | Not public |
| Document Defendant | 2026-04-13 | Not public |
| action.communication.general | 2026-04-08 | Not public |
| Receipt | 2026-04-07 | Not public |
| Cover sheet | 2026-04-07 | Not public |
| Application document Claimant | 2026-04-07 | Not public |
| action.issueOrder.order | 2026-04-01 | Not public |
| Order | 2026-04-01 | Not public |
| action.phaseChange.oralPhaseOpen | 2026-04-01 | Not public |
| action.phaseChange.interimPhaseClose | 2026-04-01 | Not public |
| Receipt | 2026-03-31 | Not public |
| Cover sheet | 2026-03-31 | Not public |
| Document | 2026-03-31 | Not public |
| Receipt | 2026-03-31 | Not public |
| Cover sheet | 2026-03-31 | Not public |
| Document | 2026-03-31 | Not public |
| Order | 2026-03-16 | Public |
| action.issueOrder.order | 2026-03-16 | Not public |
| Order | 2026-03-16 | Not public |
| action.communication.general | 2026-03-11 | Not public |
| Hearing recording reference document | 2026-03-11 | Not public |
| action.phaseChange.interimPhaseOpen | 2026-02-06 | Not public |
| action.phaseChange.writtenPhaseClose | 2026-02-06 | Not public |
| action.issueOrder.order | 2026-02-06 | Not public |
| Order | 2026-02-06 | Not public |
| action.communication.general | 2026-01-25 | Not public |
| Receipt | 2026-01-09 | Not public |
| Cover sheet | 2026-01-09 | Not public |
| Statement of rejoinder | 2026-01-09 | Not public |
| Cover sheet | 2025-12-09 | Not public |
| Exhibit document Defendant | 2025-12-09 | Not public |
| Exhibit document Defendant | 2025-12-09 | Not public |
| Exhibit document Defendant | 2025-12-09 | Not public |
| Exhibit document Defendant | 2025-12-09 | Not public |
| Exhibit document Defendant | 2025-12-09 | Not public |
| Exhibit document Defendant | 2025-12-09 | Not public |
| Exhibit document Defendant | 2025-12-09 | Not public |
| Exhibit document Defendant | 2025-12-09 | Not public |
| Exhibit document Defendant | 2025-12-09 | Not public |
| Exhibit document Defendant | 2025-12-09 | Not public |
| Exhibit document Defendant | 2025-12-09 | Not public |
| Exhibit document Defendant | 2025-12-09 | Not public |
| Exhibit document Defendant | 2025-12-09 | Not public |
| Exhibit document Defendant | 2025-12-09 | Not public |
| Exhibit document Defendant | 2025-12-09 | Not public |
| Exhibit document Defendant | 2025-12-09 | Not public |
| Exhibit document Defendant | 2025-12-09 | Not public |
| Exhibit document Defendant | 2025-12-09 | Not public |
| Exhibit document Defendant | 2025-12-09 | Not public |
| Exhibit document Defendant | 2025-12-09 | Not public |
| Exhibit document Defendant | 2025-12-09 | Not public |
| Statement of rejoinder | 2025-12-09 | Not public |
| Receipt | 2025-12-09 | Not public |
| Cover sheet | 2025-11-10 | Not public |
| Statement of reply | 2025-11-10 | Not public |
| Application to Amend Patent Defence | 2025-11-10 | Not public |
| Exhibit document Claimant | 2025-11-10 | Not public |
| Exhibit document Claimant | 2025-11-10 | Not public |
| Exhibit document Claimant | 2025-11-10 | Not public |
| Exhibit document Claimant | 2025-11-10 | Not public |
| Exhibit document Claimant | 2025-11-10 | Not public |
| Exhibit document Claimant | 2025-11-10 | Not public |
| Exhibit document Claimant | 2025-11-10 | Not public |
| Exhibit document Claimant | 2025-11-10 | Not public |
| Exhibit document Claimant | 2025-11-10 | Not public |
| Exhibit document Claimant | 2025-11-10 | Not public |
| Exhibit document Claimant | 2025-11-10 | Not public |
| Exhibit document Claimant | 2025-11-10 | Not public |
| Exhibit document Claimant | 2025-11-10 | Not public |
| Receipt | 2025-11-10 | Not public |
| action.summons.oralHearing | 2025-11-07 | Not public |
| Summons | 2025-11-07 | Not public |
| Acknowledgement-of-lodging | 2025-09-08 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2025-09-08 | Not public |
| Correction following formal checks | 2025-09-08 | Not public |
| Exhibit 19 | 2025-09-08 | Not public |
| Exhibit 37 | 2025-09-08 | Not public |
| Exhibit 66 | 2025-09-08 | Not public |
| Exhibit 25 | 2025-09-08 | Not public |
| Exhibit 45 | 2025-09-08 | Not public |
| Exhibit 68 | 2025-09-08 | Not public |
| Exhibit 51 | 2025-09-08 | Not public |
| Exhibit 36 | 2025-09-08 | Not public |
| Exhibit 49 | 2025-09-08 | Not public |
| Exhibit 73 | 2025-09-08 | Not public |
| Exhibit 81b | 2025-09-08 | Not public |
| Exhibit 15b | 2025-09-08 | Not public |
| Exhibit 54 | 2025-09-08 | Not public |
| Exhibit 43 | 2025-09-08 | Not public |
| Exhibit 83b | 2025-09-08 | Not public |
| Exhibit 74 | 2025-09-08 | Not public |
| Exhibit 33b | 2025-09-08 | Not public |
| Exhibit 75 | 2025-09-08 | Not public |
| Exhibit 20 | 2025-09-08 | Not public |
| Exhibit 57 | 2025-09-08 | Not public |
| Exhibit 78b | 2025-09-08 | Not public |
| Exhibit 84a | 2025-09-08 | Not public |
| Exhibit 50 | 2025-09-08 | Not public |
| Exhibit 18 | 2025-09-08 | Not public |
| Exhibit 60 | 2025-09-08 | Not public |
| Exhibit 79a | 2025-09-08 | Not public |
| Exhibit 84b | 2025-09-08 | Not public |
| Exhibit 44 | 2025-09-08 | Not public |
| Exhibit 38 | 2025-09-08 | Not public |
| Exhibit 23 | 2025-09-08 | Not public |
| Exhibit 52 | 2025-09-08 | Not public |
| Exhibit 79b | 2025-09-08 | Not public |
| Exhibit 59 | 2025-09-08 | Not public |
| Exhibit 85a | 2025-09-08 | Not public |
| Exhibit 46 | 2025-09-08 | Not public |
| Exhibit 80a | 2025-09-08 | Not public |
| Exhibit 82a | 2025-09-08 | Not public |
| Exhibit 69 | 2025-09-08 | Not public |
| Exhibit 55 | 2025-09-08 | Not public |
| Exhibit 39 | 2025-09-08 | Not public |
| Exhibit 15a | 2025-09-08 | Not public |
| Exhibit 82b | 2025-09-08 | Not public |
| Exhibit 16 | 2025-09-08 | Not public |
| Exhibit 47a | 2025-09-08 | Not public |
| Exhibit 70 | 2025-09-08 | Not public |
| Exhibit 64 | 2025-09-08 | Not public |
| Statement in defense | 2025-09-08 | Not public |
| Exhibit 28 | 2025-09-08 | Not public |
| Exhibit 33a | 2025-09-08 | Not public |
| Exhibit 78a | 2025-09-08 | Not public |
| Exhibit 53 | 2025-09-08 | Not public |
| Exhibit 31 | 2025-09-08 | Not public |
| Exhibit 32a | 2025-09-08 | Not public |
| Exhibit 26 | 2025-09-08 | Not public |
| Exhibit 77a | 2025-09-08 | Not public |
| Exhibit 40 | 2025-09-08 | Not public |
| Exhibit 71 | 2025-09-08 | Not public |
| Exhibit 48 | 2025-09-08 | Not public |
| Exhibit 62 | 2025-09-08 | Not public |
| Exhibit 41 | 2025-09-08 | Not public |
| Exhibit 63b | 2025-09-08 | Not public |
| Exhibit 35 | 2025-09-08 | Not public |
| Exhibit 47b | 2025-09-08 | Not public |
| Exhibit 61 | 2025-09-08 | Not public |
| Exhibit 76 | 2025-09-08 | Not public |
| Exhibit 42 | 2025-09-08 | Not public |
| Exhibit 72 | 2025-09-08 | Not public |
| Exhibit 83a | 2025-09-08 | Not public |
| Exhibit 30 | 2025-09-08 | Not public |
| Exhibit 14 | 2025-09-08 | Not public |
| Exhibit 32b | 2025-09-08 | Not public |
| Exhibit 58 | 2025-09-08 | Not public |
| Exhibit 29 | 2025-09-08 | Not public |
| Exhibit 56 | 2025-09-08 | Not public |
| Exhibit 85b | 2025-09-08 | Not public |
| Exhibit 80b | 2025-09-08 | Not public |
| Exhibit 17 | 2025-09-08 | Not public |
| Exhibit 81a | 2025-09-08 | Not public |
| Exhibit 27 | 2025-09-08 | Not public |
| Exhibit 63a | 2025-09-08 | Not public |
| Exhibit 24 | 2025-09-08 | Not public |
| Exhibit 21 | 2025-09-08 | Not public |
| Exhibit 67 | 2025-09-08 | Not public |
| Exhibit 65 | 2025-09-08 | Not public |
| Exhibit 22 | 2025-09-08 | Not public |
| Exhibit 34 | 2025-09-08 | Not public |
| Exhibit 77b | 2025-09-08 | Not public |
| Formal-checks_Request-for-correction | 2025-09-08 | Not public |
| Acknowledgement-of-lodging | 2025-09-08 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2025-09-08 | Not public |
| Receipt | 2025-09-08 | Not public |
| Exhibit 79a | 2025-09-05 | Not public |
| Exhibit 80a | 2025-09-05 | Not public |
| Exhibit 14 | 2025-09-05 | Not public |
| Exhibit 78b | 2025-09-05 | Not public |
| Exhibit 48 | 2025-09-05 | Not public |
| Exhibit 83a | 2025-09-05 | Not public |
| Exhibit 47b | 2025-09-05 | Not public |
| Exhibit 47a | 2025-09-05 | Not public |
| Exhibit 84a | 2025-09-05 | Not public |
| Application to amend the patent | 2025-09-05 | Not public |
| Exhibit 82a | 2025-09-05 | Not public |
| Exhibit 78a | 2025-09-05 | Not public |
| Exhibit 81a | 2025-09-05 | Not public |
| Exhibit 85a | 2025-09-05 | Not public |
| Exhibit 85b | 2025-09-05 | Not public |
| Exhibit 81b | 2025-09-05 | Not public |
| Exhibit 80b | 2025-09-05 | Not public |
| Exhibit 84b | 2025-09-05 | Not public |
| Exhibit 79b | 2025-09-05 | Not public |
| Exhibit 77a | 2025-09-05 | Not public |
| Exhibit 77b | 2025-09-05 | Not public |
| Exhibit 82b | 2025-09-05 | Not public |
| Exhibit 83b | 2025-09-05 | Not public |
| Request re value of the dispute and ceiling of recoverable costs | 2025-09-05 | Not public |
| Exhibit 76 | 2025-09-05 | Not public |
| Exhibit 75 | 2025-09-05 | Not public |
| Acknowledgement-of-lodging | 2025-09-05 | Not public |
| Exhibit 56 | 2025-09-05 | Not public |
| Exhibit 45 | 2025-09-05 | Not public |
| Exhibit 46 | 2025-09-05 | Not public |
| Exhibit 33a | 2025-09-05 | Not public |
| Exhibit 40 | 2025-09-05 | Not public |
| Exhibit 79a | 2025-09-05 | Not public |
| Exhibit 77a | 2025-09-05 | Not public |
| Exhibit 25 | 2025-09-05 | Not public |
| Exhibit 34 | 2025-09-05 | Not public |
| Exhibit 39 | 2025-09-05 | Not public |
| Exhibit 84a | 2025-09-05 | Not public |
| Exhibit 20 | 2025-09-05 | Not public |
| Exhibit 33b | 2025-09-05 | Not public |
| Exhibit 65 | 2025-09-05 | Not public |
| Exhibit 81a | 2025-09-05 | Not public |
| Exhibit 38 | 2025-09-05 | Not public |
| Exhibit 59 | 2025-09-05 | Not public |
| Exhibit 22 | 2025-09-05 | Not public |
| Exhibit 15b | 2025-09-05 | Not public |
| Exhibit 69 | 2025-09-05 | Not public |
| Exhibit 36 | 2025-09-05 | Not public |
| Exhibit 80b | 2025-09-05 | Not public |
| Exhibit 61 | 2025-09-05 | Not public |
| Exhibit 78a | 2025-09-05 | Not public |
| Exhibit 71 | 2025-09-05 | Not public |
| Exhibit 75 | 2025-09-05 | Not public |
| Exhibit 54 | 2025-09-05 | Not public |
| Exhibit 18 | 2025-09-05 | Not public |
| Exhibit 24 | 2025-09-05 | Not public |
| Exhibit 48 | 2025-09-05 | Not public |
| Exhibit 53 | 2025-09-05 | Not public |
| Exhibit 58 | 2025-09-05 | Not public |
| Exhibit 83b | 2025-09-05 | Not public |
| Exhibit 35 | 2025-09-05 | Not public |
| Exhibit 21 | 2025-09-05 | Not public |
| Exhibit 57 | 2025-09-05 | Not public |
| Exhibit 41 | 2025-09-05 | Not public |
| Exhibit 49 | 2025-09-05 | Not public |
| Exhibit 19 | 2025-09-05 | Not public |
| Exhibit 32b | 2025-09-05 | Not public |
| Exhibit 31 | 2025-09-05 | Not public |
| Exhibit 70 | 2025-09-05 | Not public |
| Exhibit 27 | 2025-09-05 | Not public |
| Exhibit 60 | 2025-09-05 | Not public |
| Exhibit 68 | 2025-09-05 | Not public |
| Exhibit 81b | 2025-09-05 | Not public |
| Exhibit 84b | 2025-09-05 | Not public |
| Exhibit 82b | 2025-09-05 | Not public |
| Exhibit 51 | 2025-09-05 | Not public |
| Exhibit 67 | 2025-09-05 | Not public |
| Statement in defense | 2025-09-05 | Not public |
| Exhibit 82a | 2025-09-05 | Not public |
| Exhibit 47a | 2025-09-05 | Not public |
| Exhibit 16 | 2025-09-05 | Not public |
| Exhibit 50 | 2025-09-05 | Not public |
| Exhibit 52 | 2025-09-05 | Not public |
| Exhibit 55 | 2025-09-05 | Not public |
| Exhibit 30 | 2025-09-05 | Not public |
| Exhibit 32a | 2025-09-05 | Not public |
| Exhibit 79b | 2025-09-05 | Not public |
| Exhibit 23 | 2025-09-05 | Not public |
| Exhibit 15a | 2025-09-05 | Not public |
| Exhibit 83a | 2025-09-05 | Not public |
| Exhibit 63a | 2025-09-05 | Not public |
| Exhibit 37 | 2025-09-05 | Not public |
| Exhibit 43 | 2025-09-05 | Not public |
| Exhibit 44 | 2025-09-05 | Not public |
| Exhibit 62 | 2025-09-05 | Not public |
| Exhibit 85b | 2025-09-05 | Not public |
| Exhibit 72 | 2025-09-05 | Not public |
| Exhibit 73 | 2025-09-05 | Not public |
| Exhibit 85a | 2025-09-05 | Not public |
| Exhibit 78b | 2025-09-05 | Not public |
| Exhibit 42 | 2025-09-05 | Not public |
| Exhibit 17 | 2025-09-05 | Not public |
| Exhibit 64 | 2025-09-05 | Not public |
| Exhibit 76 | 2025-09-05 | Not public |
| Exhibit 26 | 2025-09-05 | Not public |
| Exhibit 77b | 2025-09-05 | Not public |
| Exhibit 80a | 2025-09-05 | Not public |
| Exhibit 66 | 2025-09-05 | Not public |
| Exhibit 28 | 2025-09-05 | Not public |
| Exhibit 47b | 2025-09-05 | Not public |
| Exhibit 14 | 2025-09-05 | Not public |
| Exhibit 63b | 2025-09-05 | Not public |
| Exhibit 29 | 2025-09-05 | Not public |
| Exhibit 74 | 2025-09-05 | Not public |
| Headnote-and-Keywords | 2025-09-04 | Not public |
| Outcome of the Order | 2025-09-04 | Not public |
| ORDER 4 SEPTEMBER | 2025-09-04 | Public |
| Outcome of the Order | 2025-09-04 | Not public |
| ORDER 4 SEPTEMBER | 2025-09-04 | Public |
| Outcome of the Order | 2025-09-04 | Not public |
| ORDER 4 SEPTEMBER | 2025-09-04 | Public |
| Outcome of the Order | 2025-09-04 | Not public |
| ORDER 4 SEPTEMBER | 2025-09-04 | Public |
| Receipt | 2025-09-02 | Not public |
| Exhibit 13b | 2025-09-01 | Not public |
| 250901_R.9 Application_Reply to request for decision by default | 2025-09-01 | Not public |
| Exhibit 13a | 2025-09-01 | Not public |
| Receipt | 2025-09-01 | Not public |
| Generic application R.9.1 RoP re service | 2025-08-29 | Not public |
| Exhibit 6. CoA, 29 July 2024, Nec Corporation | 2025-08-29 | Not public |
| Exhibit 5. Email exchanges between LAVOIX and the Registry of 26 and 27 August 2025 | 2025-08-29 | Not public |
| Exhibit 11. 15th draft of the UPC RoP of 31 May 2013 (extract) | 2025-08-29 | Not public |
| Exhibit 10. LD Hamburg_25 August 2025_Med-El v Nurotron | 2025-08-29 | Not public |
| Exhibit 7. CoA_5 August 2024_Daedalus | 2025-08-29 | Not public |
| Exhibit 8. CoA_6 August 2024_Nera Corporation | 2025-08-29 | Not public |
| Exhibit 12. 18th draft of the UPC RoP 19 October 2015 markup version (extract) | 2025-08-29 | Not public |
| Exhibit 2. Letter to CD Milan Registry | 2025-08-29 | Not public |
| CMS screenshot | 2025-08-29 | Not public |
| Exhibit 9. CoA_5 August 2024_Panasonic | 2025-08-29 | Not public |
| Exhibit 3. Email exchanges between LAVOIX and the Milan Central Division Clerk of 11, 18 and 21 July 2025 | 2025-08-29 | Not public |
| Exhibit 1. Email exchanges between LAVOIX and the Milan Central Division Clerk of 7 and 8 July 2025 | 2025-08-29 | Not public |
| Receipt | 2025-08-28 | Not public |
| 250827_Request_for_Decision_by_Default_R355 | 2025-08-27 | Not public |
| Exhibit HRM 26_UPC_CD Paris_CFI_412-2023 | 2025-08-27 | Not public |
| Acknowledgement of access to case | 2025-08-27 | Not public |
| Receipt | 2025-08-06 | Not public |
| Exhibit HRM 24b_LD Mannheim_UPC_CFI_445_2025_Refusal_of_service_ENG | 2025-08-05 | Not public |
| Exhibit HRM 25a_LK Duesseldorf_UPC_CFI_318_2025_VU | 2025-08-05 | Not public |
| Exhibit HRM 25b_LD Duesseldorf_UPC_CFI_318_2025_Decision by Default | 2025-08-05 | Not public |
| Exhibit HRM 22_Letter dated 11 July 2025 to CD Milan Registry | 2025-08-05 | Not public |
| Exhibit HRM 24a_LK Mannheim_UPC_CFI_445_2025_AASI verweigerte Zustellung_DE | 2025-08-05 | Not public |
| 250805_UPC_CFI_552_2025_ACT_29152_2025_R9 Request re Service | 2025-08-05 | Not public |
| Exhibit HRM 23_Request for Unitary Effect | 2025-08-05 | Not public |
| Exhibit HRM 21_UPC_CFI_552_2025_ACT_29152_2025_Screenshot | 2025-08-05 | Not public |
| Notification Of Service | 2025-07-09 | Not public |
| Proof of service | 2025-07-09 | Not public |
| communicationCheck | 2025-06-27 | Not public |
| communicationCheck | 2025-06-27 | Not public |
| communicationCheck | 2025-06-27 | Not public |
| communicationCheck | 2025-06-27 | Not public |
| communicationCheck | 2025-06-27 | Not public |
| communicationCheck | 2025-06-27 | Not public |
| communicationCheck | 2025-06-27 | Not public |
| communicationCheck | 2025-06-27 | Not public |
| communicationCheck | 2025-06-27 | Not public |
| communicationCheck | 2025-06-27 | Not public |
| communicationCheck | 2025-06-27 | Not public |
| Document from EPO | 2025-06-27 | Not public |
| Document from EPO | 2025-06-26 | Not public |
| Document from EPO | 2025-06-26 | Not public |
| Document from EPO | 2025-06-26 | Not public |
| Document from EPO | 2025-06-26 | Not public |
| Document from EPO | 2025-06-26 | Not public |
| Document from EPO | 2025-06-26 | Not public |
| Document from EPO | 2025-06-25 | Not public |
| Document from EPO | 2025-06-25 | Not public |
| Document from EPO | 2025-06-25 | Not public |
| Document from EPO | 2025-06-25 | Not public |
| Document from EPO | 2025-06-25 | Not public |
| Document from EPO | 2025-06-25 | Not public |
| Letter-for-Service | 2025-06-20 | Not public |
| Panel-Appointment | 2025-06-20 | Not public |
| EPO-Request-for-case-pending | 2025-06-20 | Not public |
| Acknowledgement-of-lodging | 2025-06-20 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2025-06-20 | Not public |
| Exhibit HRM 03_Stadler-2003 | 2025-06-20 | Not public |
| Exhibit HRM 06a_Twitter post Dr Kevin Olival | 2025-06-20 | Not public |
| Exhibit HRM 01_A1 application EP403 | 2025-06-20 | Not public |
| Exhibit HRM 15_Lescure | 2025-06-20 | Not public |
| 250618_Revocation action | 2025-06-20 | Not public |
| Exhibit HRM 12_Brown-2019 | 2025-06-20 | Not public |
| Exhibit HRM 13_Sheahan-2020 | 2025-06-20 | Not public |
| Exhibit HRM 07_Wuhan seafood market pneumonia virus isolate Wuhan Hu 1 complete geno Nucleotide NCBI | 2025-06-20 | Not public |
| Exhibit HRM 20_CIDRAP website article | 2025-06-20 | Not public |
| Exhibit HRM 09_Gillings website article | 2025-06-20 | Not public |
| Exhibit HRM 14_Holshue | 2025-06-20 | Not public |
| Exhibit HRM 04_Peck-2015 | 2025-06-20 | Not public |
| Exhibit HRM 05_Virological - Novel 2019 coronavirus genome - SARS-CoV-2 coronavirus | 2025-06-20 | Not public |
| Exhibit HRM 18_Beigel 2019 | 2025-06-20 | Not public |
| Exhibit HRM 11_Sheahan-2017 | 2025-06-20 | Not public |
| Exhibit HRM 17_BBC article | 2025-06-20 | Not public |
| Exhibit HRM 06b_Enlarged version of phylogenetic tree | 2025-06-20 | Not public |
| Exhibit HRM 02a_Proof of payment_DE | 2025-06-20 | Not public |
| Exhibit HRM 10_Nature Microbiology | 2025-06-20 | Not public |
| Exhibit HRM 19_Lo 2017 | 2025-06-20 | Not public |
| Exhibit HRM 08_Baric declaration_literature | 2025-06-20 | Not public |
| Exhibit HRM 02a_Proof of payment_DE | 2025-06-20 | Not public |
| Exhibit HRM 16_Agostini-2018 | 2025-06-20 | Not public |
| Formal-checks_Request-for-correction | 2025-06-19 | Not public |
| Exhibit HRM 07_Wuhan seafood market pneumonia virus isolate Wuhan Hu 1 complete geno Nucleotide NCBI | 2025-06-18 | Not public |
| Exhibit HRM 06b_Enlarged version of phylogenetic tree | 2025-06-18 | Not public |
| Exhibit HRM 02a_Proof of payment_DE | 2025-06-18 | Not public |
| Exhibit HRM 14_Holshue | 2025-06-18 | Not public |
| Exhibit HRM 05_Virological - Novel 2019 coronavirus genome - SARS-CoV-2 coronavirus | 2025-06-18 | Not public |
| Exhibit HRM 19_Lo 2017 | 2025-06-18 | Not public |
| Exhibit HRM 02a_Proof of payment_DE | 2025-06-18 | Not public |
| Exhibit HRM 01_A1 application EP403 | 2025-06-18 | Not public |
| Exhibit HRM 11_Sheahan-2017 | 2025-06-18 | Not public |
| Exhibit HRM 10_Nature Microbiology | 2025-06-18 | Not public |
| 250618_Revocation action | 2025-06-18 | Not public |
| Exhibit HRM 06a_Twitter post Dr Kevin Olival | 2025-06-18 | Not public |
| Exhibit HRM 12_Brown-2019 | 2025-06-18 | Not public |
| Exhibit HRM 15_Lescure | 2025-06-18 | Not public |
| Exhibit HRM 20_CIDRAP website article | 2025-06-18 | Not public |
| Exhibit HRM 09_Gillings website article | 2025-06-18 | Not public |
| Exhibit HRM 08_Baric declaration_literature | 2025-06-18 | Not public |
| Exhibit HRM 13_Sheahan-2020 | 2025-06-18 | Not public |
| Exhibit HRM 04_Peck-2015 | 2025-06-18 | Not public |
| Exhibit HRM 16_Agostini-2018 | 2025-06-18 | Not public |
| Exhibit HRM 17_BBC article | 2025-06-18 | Not public |
| Exhibit HRM 03_Stadler-2003 | 2025-06-18 | Not public |
The skilled person (virologist researching antiviral drugs for coronaviruses) would have had a high expectation of success that Remdesivir would be effective against SARS-CoV-2, based on prior art documents (HRM 09, HRM 10, HRM 11, HRM 12, HRM 16) showing broad-spectrum anti-coronavirus activity via highly conserved RdRP
ClaimantLegal basis: Art. 56 EPC; EPO Guidelines G-VII-13; UPC_CoA 464/24 (25 November 2025)The objective technical problem was finding a drug with antiviral activity against SARS-CoV-2, not merely testing Remdesivir against the new virus; but given that the prior art clearly suggested Remdesivir as the solution, the claimed invention lacked inventive step
ClaimantLegal basis: Art. 56 EPC; UPC_CoA_528/2024 (Amgen v Sanofi, 25 November 2025) §11-12Formula I in the granted claims already encompassed both isomers due to the chiral phosphorus in the drawing, making the Main Request amendment (removing 'geometric isomer') admissible under Art. 123 and 84 EPC, though still not inventive
ClaimantLegal basis: Art. 123(3) EPC; Art. 84 EPC; R. 50.2 RoP
The patent is insufficiently disclosed because Formula I's stereochemistry at phosphorus is undefined, constituting an undue burden for the skilled person to identify/separate the two isomers
ClaimantLegal basis: Art. 83 EPC / Art. 138(1)(b) EPCThe skilled person would not have had a reasonable expectation of success because differences in the NiRAN subdomain and exonuclease proofreading activity (nsp14) of SARS-CoV-2 introduced substantial uncertainty about Remdesivir's efficacy; the skilled person would only have had a 'hope of success'
RespondentLegal basis: Art. 56 EPCThe skilled person should be defined as an independent virologist with no links to any pharmaceutical company, and the prior art documents relied upon by the claimant were commercially motivated and lacked scientific credibility
RespondentLegal basis: Art. 56 EPCThe patent should be maintained in amended form per the Main Request or one of the eight Auxiliary Requests
RespondentLegal basis: R. 50.2 RoP; Art. 123 EPC; Art. 84 EPCThe value of proceedings should be set at €6,800 (cost of the patent application) rather than €20 million
RespondentLegal basis: R. 152.3 RoP; R. 370.6 RoP